You are here

Article Text

Article menu
Download PDFPDF
Case Reports
Remission of metastatic cervical adenocarcinoma with weekly paclitaxel
  1. S. Ota,
  2. T. Sugiyama,
  3. K. Ushijima,
  4. K. Fujiyoshi,
  5. K. Komai,
  6. N. Hirai,
  7. T. Nishida and
  8. T. Kamura
  1. Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
  1. Address correspondence and reprint requests to: Dr. Toru Sugiyama, Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume City, Fukuoka, 830–0011 Japan.

Abstract

We report the use of paclitaxel in the successful treatment of a patient with recurrent adenocarcinoma of the cervix. Paclitaxel, 70 mg/m2 by 1-h infusion weekly, was administered to a 59-year-old patient with cervical adenocarcinoma showing lung metastasis. She showed partial clinical response after seven cycles, and at the completion of 20 cycles she showed complete response, which was confirmed by chest X-ray and computed tomography scan. Toxicities including neurotoxicity were mild. She showed an objective response to treatment for over 8 months, and she enjoyed a favorable quality of life during and after treatment. Weekly paclitaxel was very well tolerated, yet was effective for recurrent cervical adenocarcinoma.

  • adenocarcinoma
  • cervical cancer
  • paclitaxel

https://doi.org/10.1136/ijgc-00009577-200103000-00012

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.